Diane Baniewicz

Children's Hospital of Philadelphia — United States

Medicine · Health Sciences

15h-index1.2kcitations32works4.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(25), Acute Lymphoblastic Leukemia research(13), Virus-based gene therapy research(5), Cancer Immunotherapy and Biomarkers(3), Lymphoma Diagnosis and Treatment(2)

Publications32 total

CD19 CAR T-cell Therapy in Infant B-ALL: Durable Remissions, Relapse Patterns, and Molecular Correlates
Transplantation and Cellular Therapy·2026
Next Generation Sequencing Minimal Residual Disease in Pediatric B-ALL after CD19 and/or CD22 CAR T-cell Therapy: Depth and Kinetics of Response Predict Relapse Risk.
Transplantation and Cellular Therapy·2026
High Rates of Clinically Significant Late Infections and Recurrent Sinopulmonary Disease in Long-Term Survivors after CD19 CAR T-cell Therapy for Pediatric B-ALL
Transplantation and Cellular Therapy·2026
Humanized CD19 chimeric antigen receptor (CAR) T-cell therapy for high-risk and post-CAR relapse of B-cell acute lymphoblastic leukemia
Blood·2025
CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL
Blood·2025Open Access
CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia
Blood·2025
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 11 citedOpen Access
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy
Blood Advances·2024· 4 citedOpen Access
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia
Blood Advances·2024· 25 citedOpen Access
CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
Blood·2022· 6 cited
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy
Blood·2022· 33 citedOpen Access
Impact of socioeconomic status on survival after CD19 CART therapy.
Journal of Clinical Oncology·2022
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy
Blood·2021· 109 citedOpen Access
Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Blood·2021· 18 cited
Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL
Blood·2021· 3 cited
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials
The Lancet Haematology·2021· 114 citedOpen Access
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Journal of Clinical Oncology·2021· 179 citedOpen Access
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
Journal of Clinical Oncology·2021· 202 citedOpen Access
Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Biology of Blood and Marrow Transplantation·2020· 15 citedOpen Access
Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
Blood·2019· 11 cited
page 1 of 2Next →

Frequent Co-authors

Colleen Callahan(29), Stephan A. Grupp(27), Shannon L. Maude(24), Amanda M. DiNofia(23), Susan R. Rheingold(22), Regina M. Myers(20), Lisa Wray(18), Richard Aplenc(17), Yimei Li(16), Allison Barz Leahy(16), Carl H. June(14), David T. Teachey(12), David M. Barrett(9), Stephan Kadauke(8), Simon F. Lacey(8), Vanessa Gonzalez(8), Caroline Diorio(8), Bruce L. Levine(7), Hongyan Liu(7), Susan McClory(7)